One of the most important pharmaceutical properties of a drug candidate to be determined during any pre-clinical discovery is the effect of the specific test compound on the activity of Cytochrome P450, a key enzyme involved in drug metabolism. The purpose of this project was to validate a Cytochrome p450 2C8 (CYP2C8) enzyme inhibition assay in development at Charles River Labs (Worcester). The assay quantitates the in vitro inhibition of CYP2C8-specific drug substrates Amodiaquine (AMOD) and Paclitaxel (PACL). The data presented here validate the assay.

• This report represents the work of one or more WPI undergraduate students submitted to the faculty as evidence of completion of a degree requirement. WPI routinely publishes these reports on its website without editorial or peer review.

Creator

• Schulze, Matthew George

Contributors

• Mitchell, Sarah
• Sheldon, Adrian
• Walton, Patty

Publisher

• Worcester Polytechnic Institute

Identifier

• E-project-042408-160916

Advisor

• Adams, David S.

Year

• 2008

Sponsor

• Charles River Laboratories Pre-clinical Services

Date created

• 2008-04-24

Resource type

• Major Qualifying Project

Major

• Biology & Biotechnology

Rights statement

• In Copyright